On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

Johnson & Johnson's Spravato therapy for treatment ... the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from ...

Johnson & Johnson has priced its new Spravato ... has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value threshold.

The federal government has bankrolled the use of an artificial ketamine nasal spray to combat treatment-resistant depression, ...

Also Read: Johnson & Johnson, Protagonist Tout Positive Results For ... and Simponi/Simponi Aria in immunology, Spravato (esketamine) Neuroscience, and Xarelto in cardiovascular. Growth was partially ...

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.